Abstract 190P
Background
The PACIFIC trial established consolidation D as standard of care (SoC) for patients (pts) with urNSCLC and no progression after concurrent CRT (cCRT). PACIFIC-R (NCT03798535) has since supported the efficacy and tolerability of this regimen in a real-world population. We present survival outcomes from the final PACIFIC-R data extraction, with >5 yrs of follow-up.
Methods
PACIFIC-R is an international, observational study of adults with urNSCLC who received D (10 mg/kg IV Q2W) in an AstraZenecainitiated early access program (Sep 2017–Dec 2018) after completing cCRT or sequential CRT (sCRT) with no disease progression. Primary endpoints were overall survival (OS) and real-world progression-free survival (rwPFS; investigator assessed).
Results
At data cutoff (16 Sep 2024), the full analysis set comprised 1153 pts from 10 countries (median follow-up in censored pts: 63.5 mos for rwPFS, 67.5 mos for OS). Median age was 65.0 yrs (range 26–88), disease stage was IIIA in 46.4% and IIIB/C in 53.6% of pts, and 98.4% had an ECOG PS of 0 or 1. Pts received a median of 23.0 (range 1–99) infusions; 22.1% received D for >12 mos. Median rwPFS was 24.3 mos (95% CI 20.3–28.4); 5-yr rwPFS was 35.2% (95% CI 32.4–38.1). Median OS was 59.0 mos (95% CI 52.7–64.3); 5-yr OS was 49.2% (95% CI 46.2–52.2). Encouraging results were observed across subgroups, including among pts who received D after either cCRT or sCRT (median rwPFS [95% CI]: 25.8 [20.9–31.8] vs 23.2 [16.9–29.5] mos; median OS: 63.1 [57.3–73.5] vs 47.1 [35.3–58.1] mos) and irrespective of PD-L1 tumor cell (TC) expression (TC ≥1% vs
Conclusions
With mature OS and rwPFS, final analyses from PACIFIC-R support the long-term benefit of consolidation D after CRT with data from a large cohort in a real-world setting. Encouraging outcomes were observed across subgroups, supporting use of the PACIFIC regimen as the global SoC for pts with urNSCLC.
Clinical trial identification
NCT03798535 First posted 10 Jan 2019; Last Updated 28 October 2024.
Editorial acknowledgement
Medical writing support for the development of this abstract, under the direction of the authors, was provided by Eric Exner, MD, PhD, of Ashfield MedComms (New York, NY, USA), an Inizio company, and was funded by AstraZeneca.
Legal entity responsible for the study
AstraZeneca.
Funding
AstraZeneca.
Disclosure
N. Girard: Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Regeneron, AbbVie, Amgen, Lilly, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen, Pierre Fabre, BeiGene; Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, Pfizer, Amgen, MSD, Sanofi, Gilead, Janssen; Financial Interests, Personal, Officer: Edimark; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Personal, Other, Family member is an employee: AstraZeneca. J. Bar: Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Writing Engagements: BMS, Medison; Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, MSD, Merck-Serono, Roche, Takeda; Financial Interests, Institutional, Research Grant: MSD, AstraZeneca, Roche, AbbVie; Non-Financial Interests, Institutional, Principal Investigator: MSD, AstraZeneca, AbbVie, Roche, Janssen. D. Christoph: Financial Interests, Personal, Other, Travel support: AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Takeda; Financial Interests, Institutional, Other, Consulting fees: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Takeda; Financial Interests, Institutional, Advisory Board, Payment or honoraria, payment for expert testimony, support for attending meetings and/or travel: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sanofi, and Takeda. R. Fietkau: Financial Interests, Personal, Invited Speaker: Merck Serono, AstraZeneca, MSD, Novocure, Siemens; Financial Interests, Personal, Speaker’s Bureau: Merck Serono, AstraZeneca, MSD, Novocure, Siemens, Promedicis, Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: MSD, AstraZeneca, Novocure; Financial Interests, Institutional, Research Grant: AstraZeneca, MSD, Novocure, Siemens. M.C. Garassino: Financial Interests, Institutional, Research Grant: AstraZeneca, Merck; Financial Interests, Personal, Other, Personal fees: AstraZeneca, Merck, Roche, Bristol Myers Squibb, Celgene, Boehringer Ingelheim, Novartis, GSK, Pfizer, Eli Lilly, and Takeda. P. Garrido Lopez: Financial Interests, Personal, Invited Speaker: Amgen, Janssen, Roche; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, F. Hoffmann-La Roche, GSK, Janssen, Medscape, Merck KGaA, MSD, Novartis, PeerVoice, Pfizer, Regeneron, Sanofi Genzyme, Seattle Genetics and Takeda. V.D. Haakensen: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Pfizer, J&J; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, Novartis, MSD. J.T.J.N. Hiltermann: Other, Institutional, Research Grant: Roche/AstraZeneca/BMS; Non-Financial Interests, Institutional, Principal Investigator: Roche/AstraZeneca/BMS/ MSD/GSK/Amgen/Gilead; Other, Personal, Member: ASCO/ESMO/IASLC/NVALT; Other, Institutional, Advisory Role: CieBOM. S.C. Kao: Financial Interests, Personal and Institutional, Invited Speaker: MSD, BMS, Roche, AstraZeneca, Pfizer, Takeda, BeiGene, Daiichi Sankyo; Financial Interests, Personal and Institutional, Advisory Board: Advisory board AstraZeneca, Pfizer, MSD, BMS, Roche, Amgen, BeiGene, Boehringer Ingelheim, Daiichi Sankyo, Takeda Financial Personal & Institutional; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Personal, Sponsor/Funding: Pfizer. F. McDonald: Financial Interests, Personal and Institutional, Invited Speaker: AstraZeneca; Financial Interests, Personal and Institutional, Speaker’s Bureau: AstraZeneca; Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca. M.T. Moskovitz: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Writing Engagements: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Bayer, Amgen, Megapharm, Pfizer; Financial Interests, Personal, Research Grant: AstraZeneca; Financial Interests, Personal, Other: AstraZeneca, MSD, Roche, BMS, Pfizer, Merck. S. Peters: Financial Interests, Personal, Other, Participation as a subinvestigator in trials (institutional financial support for clinical trials): Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, GSK, Illumina, Eli Lilly, Merck Sharp & Dohme, Merck Serono, Mirati, Novartis, Pfizer, Phosplatin Therapeutics, and Roche/Genentech; Financial Interests, Institutional, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Biocartis, Boehringer Ingelheim, Bristol Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, ecancer, Eli Lilly, Elsevier, Fishawack, Foundation Medicine, Illumina, Imedex, IQVIA, Incyte, Janssen, Medscape, Merck, RMEI, Roche/Genentech, RTP, Sanofi, Seattle Genetics, and Takeda; Financial Interests, Institutional, Other, Payment or honoraria: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, ecancer, Eli Lilly, Illumina, Imedex, Medscape, Merck Sharp & Dohme, Novartis, PER, Pfizer, Prime, Roche/ Genentech, RTP, Sanofi, and Takeda; Financial Interests, Institutional, Other, Travel support: AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche/Genentech, and Takeda. S. Siva: Financial Interests, Institutional, Advisory Board: AstraZeneca; Financial Interests, Institutional, Research Grant: Merck Sharpe Dohme, Varian Industries, Bayer Pharmaceuticals. B. Solomon: Financial Interests, Personal, Invited Speaker: Pfizer, Roche, Merck Sharpe Dohme, GSK; Financial Interests, Personal, Advisory Board: AstraZeneca; Roche; Pfizer; Bristol Myers Squibb; Merck Sharpe Dohme; Merck Serono; Amgen; GSK; Financial Interests, Personal, Member of Board of Directors: International Association for the Study of Lung Cancer (IASLC); Thoracic Oncology Group of Australia (TOGA); Cancer Council Victoria. Y. Qiao, S. Anand, P. Chander: Financial Interests, Personal, Full or part-time Employment: AstraZeneca; Financial Interests, Personal, Stocks/Shares: AstraZeneca. A.R. Filippi: Financial Interests, Personal, Invited Speaker: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: AstraZeneca, Roche, Takeda; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Institutional, Research Grant: AstraZeneca; Other, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Personal, Sponsor/Funding: AstraZeneca, MSD, Roche; Financial Interests, Personal, Advisory Role: AstraZeneca, Radiomics.bio. All other authors have declared no conflicts of interest.